The Potential Public Health Benefit of mRNA-1010 for Influenza Among Older Adults >=65 Years in the United States

mRNA-1010 may prevent an additional 232,200 symptomatic influenza infections and 2,200 influenza-related deaths among U.S. adults aged ≥65 years compared to HD-IIV.

• Why it matters: Older adults face high risks of severe influenza complications, and current egg-based vaccines may be affected by egg-adapted mutations, potentially reducing effectiveness.
• What they did: A decision-analytic model estimated the clinical impact of mRNA-1010 versus HD-IIV using CDC data, clinical trial results, and literature on egg adaptation, projecting outcomes over one year.
• The result: The findings suggest mRNA-1010 could significantly reduce influenza burden in older adults, with outcomes most sensitive to influenza incidence and vaccine effectiveness.